Less than two years after establishing a foothold in Morocco, the Indian Biocon Biologics intends to move up a gear there.
The global biosimilar specialist plans to take its subsidiary Biocon Biologics Morocco to a new stage after a purely commercial start-up.
Also, the pharmaceutical laboratory of Indian origin which has established itself in a few years as a global giant in biosimilar products (pharmaceutical products made from living organisms), has just injected some 5 million dirhams into its subsidiary Biocon Biologics Morocco in parallel with the extension of its corporate purpose towards the activity of pharmaceutical establishment.
Read also | The flagship product of disappearing laboratories!
For the moment, nothing has filtered out on the details of Biocon Biologics Morocco’s industrial project, but according to sources close to the Indian group created in 1978, the future production site of this entity will be built in Casablanca and will have to mobilize an additional budget. of 100 million dirhams. For the moment, the activity of Biocon Biologics Morocco remains very limited with a turnover of barely 4 million dirhams for the financial year ended June 30, 2024 and thanks to a handful of products like Hertraz , Abevmy, Fulphila, Semglee and Hulio. But the entry into service of its future industrial site should boost the revenues of the Moroccan subsidiary of Biocon Biologics thanks to the expansion of its product portfolio which will have to tackle therapeutic classes such as cancer, diabetes and other diseases. autoimmune.
Read also | Indoka Laboratories: a newcomer in the processing of cannabis for medical use
Remember, the Biocon Biologics group, whose world headquarters is located in Bengaluru in India, is one of the pharmaceutical laboratories developing the most in biosimilars with around twenty new products in the final phase of development, a research & development effort which has surpassed the billion-dollar mark over the past two decades.
Business
